A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype
暂无分享,去创建一个
Ruth S. Waterman | R. Waterman | Aline M. Betancourt | Suzanne L. Tomchuck | Sarah L. Henkle | Suzanne L Tomchuck
[1] Sergio Romagnani,et al. Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .
[2] Sergio Romagnani,et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.
[3] L. O’Neill,et al. New insights into the regulation of TLR signaling , 2006, Journal of leukocyte biology.
[4] C. Hughes,et al. Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.
[5] Hong Shen,et al. TGF-β1/Smad7 Signaling Stimulates Renal Tubulointerstitial Fibrosis Induced by AAI , 2008 .
[6] J. Massagué,et al. The transforming growth factor-beta family. , 1990, Annual review of cell biology.
[7] A. Nauta,et al. Modulation of Immune Responses by Mesenchymal Stem Cells , 2007, Annals of the New York Academy of Sciences.
[8] Jun Tan,et al. Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.
[9] A. Caplan. Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. , 1995, Connective tissue research.
[10] S. Beyth,et al. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. , 2007, Experimental hematology.
[11] E. Lombardo,et al. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. , 2009, Tissue engineering. Part A.
[12] M. Pevsner-Fischer,et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. , 2007, Blood.
[13] M. Pittenger,et al. Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.
[14] U. Lendahl,et al. Cross-talk between the Notch and TGF-β signaling pathways mediated by interaction of the Notch intracellular domain with Smad3 , 2003, The Journal of cell biology.
[15] Y. Bae,et al. Role of Toll‐Like Receptors on Human Adipose‐Derived Stromal Cells , 2006, Stem cells.
[16] Keystone Symposia. Cell- & Tissue-based Therapy , 2004 .
[17] Stefan W Krause,et al. Species-specific Regulation of Toll-like Receptor 3 Genes in Men and Mice* , 2003, Journal of Biological Chemistry.
[18] É. Mezey,et al. Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands , 2009, Journal of Molecular Medicine.
[19] T. Ottenhoff,et al. Phenotypic and functional profiling of human proinflammatory type‐1 and anti‐inflammatory type‐2 macrophages in response to microbial antigens and IFN‐γ‐ and CD40L‐mediated costimulation , 2006, Journal of leukocyte biology.
[20] Mohamed H. Sayegh,et al. Immunomodulation by Mesenchymal Stem Cells , 2008, Diabetes.
[21] Krisztián Németh,et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.
[22] B. S. Lee,et al. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. , 2001, The Journal of clinical endocrinology and metabolism.
[23] S. Akira,et al. Toll-like Receptors and Their Signaling Mechanisms , 2003, Scandinavian journal of infectious diseases.
[24] G. Hoyle,et al. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. , 2007, Experimental hematology.
[25] F. Marini,et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells , 2009, Proceedings of the National Academy of Sciences.
[26] Ulrich Göbel,et al. bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .
[27] P. Matzinger. The Danger Model: A Renewed Sense of Self , 2002, Science.
[28] S. Coffelt,et al. Leucine Leucine-37 Uses Formyl Peptide Receptor–Like 1 to Activate Signal Transduction Pathways, Stimulate Oncogenic Gene Expression, and Enhance the Invasiveness of Ovarian Cancer Cells , 2009, Molecular Cancer Research.
[29] C. Carlo-Stella,et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.
[30] Alberto Mantovani,et al. Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.
[31] N. Rouas-Freiss,et al. Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.
[32] S. Perez,et al. Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.
[33] A. Tabilio,et al. Mesenchymal cells recruit and regulate T regulatory cells. , 2008, Experimental hematology.
[34] D. Mevorach,et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.
[35] Winfried Brenner,et al. Assessment of the Tissue Distribution of Transplanted Human Endothelial Progenitor Cells by Radioactive Labeling , 2003, Circulation.
[36] D. Banerjee,et al. The therapeutic potential of mesenchymal stem cells , 2007, Expert opinion on biological therapy.
[37] N. Gallay,et al. The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities , 2007, Stem cells.
[38] D. Prockop. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[39] A. Nauta,et al. Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.
[40] Ruth S. Waterman,et al. Ovarian cancers overexpress the antimicrobial protein hCAP‐18 and its derivative LL‐37 increases ovarian cancer cell proliferation and invasion , 2007, International journal of cancer.
[41] Frank P Barry,et al. Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.
[42] A. P. Robinson,et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses , 2008, Proceedings of the National Academy of Sciences.
[43] F. Lanza,et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. , 2008, Cytotherapy.
[44] A. Uccelli,et al. Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.
[45] M. Andreeff,et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. , 2005, Cancer research.
[46] L. Cosmi,et al. Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.
[47] T. Golde,et al. Notch 1 and TGF 1 cooperatively regulate Foxp 3 expression and the maintenance of peripheral regulatory T cells , 2008 .
[48] T. Golde,et al. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. , 2008, Blood.
[49] J J Padgett,et al. A renewed sense of self. , 1994, Journal of psychosocial nursing and mental health services.
[50] O. Ringdén,et al. Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.
[51] Kazuya Sato,et al. Cell and gene therapy using mesenchymal stem cells (MSCs). , 2008, Journal of autoimmunity.
[52] A. Caplan,et al. The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.
[53] M. Liebergall,et al. The Induction of APC with a Distinct Tolerogenic Phenotype via Contact-Dependent STAT3 Activation , 2009, PloS one.
[54] H. S. Warren,et al. Toll-like receptors. , 2005, Critical care medicine.
[55] Ruth S. Waterman,et al. Toll‐Like Receptors on Human Mesenchymal Stem Cells Drive Their Migration and Immunomodulating Responses , 2008, Stem cells.
[56] M. Pittenger,et al. Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.
[57] R. Romieu-Mourez,et al. Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1 , 2009, The Journal of Immunology.
[58] J. Pollard. Trophic macrophages in development and disease , 2009, Nature Reviews Immunology.
[59] D J Prockop,et al. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells , 1999, Journal of cellular biochemistry.
[60] Sankar Ghosh,et al. Recognition and signaling by toll-like receptors. , 2006, Annual review of cell and developmental biology.